Publications

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

 55
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Tags:

Previous Article

Human Schwann cell lipid dysregulation and plasma membrane perturbation in Charc...

Next Article

FerroTerminator1 as a potent therapeutic drug for MASH

Related Posts

MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review

MicroRNA biomarkers as next-generation diagnostic tools...

 85

Leucine restriction ameliorates Fusobacterium nucleatum-driven malignant progression and radioresistance in nasopharyngeal carcinoma

Leucine restriction ameliorates Fusobacterium nucleatum...

 68

Mitochondrial respiration atlas reveals differential changes in mitochondrial function across sex and age

Mitochondrial respiration atlas reveals differential ch...

 84